HTT and juvenile Huntington disease: Huntington was almost 22 when he presented his seminal work, and by coincidence it was 22 years after the discovery of the HTT gene that the first injection of an ASO therapeutic targeting huntingtin production in the brain was administered into the spinal fluid of a patient with Huntington’s disease in September 2015 in either Vancouver or London (the ongoing safety trial remains double-blinded).